<DOC>
	<DOC>NCT01462370</DOC>
	<brief_summary>This is a study to determine the overall analgesic effect of a single oral dose of etoricoxib compared to ibuprofen in participants with moderate-to-severe primary dysmenorrhea.</brief_summary>
	<brief_title>Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)</brief_title>
	<detailed_description>Participants who meet all the study entry criteria will be randomly allocated to 2 possible sequences of the 2 treatment regimens over the course of 2 menstrual cycles. In treatment sequence 1, participants will receive etoricoxib 120 mg daily in menstrual cycle 1, and ibuprofen up to 2400 mg/daily in menstrual cycle 2. In treatment sequence 2, participants will receive ibuprofen up to 2400 mg/daily in menstrual cycle 1 and etoricoxib 120 mg daily in menstrual cycle 2.</detailed_description>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Agree to remain abstinent or use doublebarrier contraception throughout the study. Participants who are status post tubal ligation are exempt from this requirement. Moderate or severe primary dysmenorrhea during a minimum of 4 of the previous 6 menstrual cycles. Moderate: Overthecounter analgesics provide significant relief in most menstrual cycles; discomfort interferes with usual activity. Severe: Overthecounter analgesics not consistently effective, or prescription analgesics required in at least some menstrual cycles; discomfort is incapacitating causing an inability to work or do usual activity. Willing to limit alcohol intake to 2 drinks or equivalent per day for the duration of the study and followup period as well as to avoid exercise during the first 24 hours postdose in each menstrual cycle. Able to read, understand, and complete diary. Use of an intrauterine device. Pregnant, breast feeding, or &lt;6 weeks postpartum. Active gastric ulcer or history of inflammatory bowel disease. Uncontrolled hypertension. Uncontrolled diabetes mellitus or renal disease. Class IIIV congestive heart failure. Coronary artery bypass graft surgery, angioplasty, myocardial infarction, cerebrovascular accident or transient ischemic attack within the past 6 months. Unstable angina. Mild, moderate, or severe hepatic insufficiency. Any personal or family history of an inherited or acquired bleeding disorder. History of neoplastic disease; Exceptions: 1)adequately treated basal cell carcinoma or carcinoma in situ of the cervix; 2) other malignancies which have been successfully treated &gt; or equal to 5 years prior to screening. Participants with a history of leukemia, lymphoma, malignant melanoma, and myeloproliferative disease are ineligible for the study regardless of the time since treatment. Allergic to etoricoxib, ibuprofen, acetaminophen, indomethacin, or other nonsteroidal antiinflammatory drugs (NSAIDs), or cyclooxygenase (COX)2 inhibitors, or to components in Saridon (propyphenazone/paracetamol/caffeine). Recent history of chronic analgesic or tranquilizer use or dependence. Morbidly obese and demonstrates significant health problems stemming from the obesity. Current user of recreational or illicit drugs or had a recent history of drug or alcohol abuse or dependence. Participated in another clinical study within the last 4 weeks. Not able to swallow oral medications: surgical or anatomical conditions that will preclude from swallowing and absorbing oral medications on an ongoing basis.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>